Cellectar Biosciences (CLRB) Competitors $2.06 +0.03 (+1.48%) (As of 09:52 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CLRB vs. OCUP, MLND, BMEA, CMPS, ITOS, JSPR, TSHA, RZLT, PRQR, and ACBShould you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Ocuphire Pharma (OCUP), Millendo Therapeutics (MLND), Biomea Fusion (BMEA), COMPASS Pathways (CMPS), iTeos Therapeutics (ITOS), Jasper Therapeutics (JSPR), Taysha Gene Therapies (TSHA), Rezolute (RZLT), ProQR Therapeutics (PRQR), and Aurora Cannabis (ACB). These companies are all part of the "medical" sector. Cellectar Biosciences vs. Ocuphire Pharma Millendo Therapeutics Biomea Fusion COMPASS Pathways iTeos Therapeutics Jasper Therapeutics Taysha Gene Therapies Rezolute ProQR Therapeutics Aurora Cannabis Ocuphire Pharma (NASDAQ:OCUP) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations. Do insiders & institutionals have more ownership in OCUP or CLRB? 15.0% of Ocuphire Pharma shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 8.7% of Ocuphire Pharma shares are held by insiders. Comparatively, 3.7% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is OCUP or CLRB more profitable? Cellectar Biosciences has a net margin of 0.00% compared to Ocuphire Pharma's net margin of -85.75%. Cellectar Biosciences' return on equity of 0.00% beat Ocuphire Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Ocuphire Pharma-85.75% -30.19% -27.55% Cellectar Biosciences N/A N/A -176.62% Which has better earnings & valuation, OCUP or CLRB? Ocuphire Pharma has higher revenue and earnings than Cellectar Biosciences. Ocuphire Pharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcuphire Pharma$16.45M1.84-$9.99M-$0.49-2.39Cellectar BiosciencesN/AN/A-$37.98M-$2.53-0.80 Does the media refer more to OCUP or CLRB? In the previous week, Cellectar Biosciences had 4 more articles in the media than Ocuphire Pharma. MarketBeat recorded 4 mentions for Cellectar Biosciences and 0 mentions for Ocuphire Pharma. Ocuphire Pharma's average media sentiment score of 0.00 equaled Cellectar Biosciences'average media sentiment score. Company Overall Sentiment Ocuphire Pharma Neutral Cellectar Biosciences Neutral Do analysts recommend OCUP or CLRB? Ocuphire Pharma currently has a consensus target price of $16.00, indicating a potential upside of 1,267.52%. Cellectar Biosciences has a consensus target price of $21.00, indicating a potential upside of 934.48%. Given Ocuphire Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ocuphire Pharma is more favorable than Cellectar Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocuphire Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Cellectar Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer OCUP or CLRB? Cellectar Biosciences received 204 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. However, 69.81% of users gave Ocuphire Pharma an outperform vote while only 55.92% of users gave Cellectar Biosciences an outperform vote. CompanyUnderperformOutperformOcuphire PharmaOutperform Votes3769.81% Underperform Votes1630.19% Cellectar BiosciencesOutperform Votes24155.92% Underperform Votes19044.08% Which has more volatility & risk, OCUP or CLRB? Ocuphire Pharma has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500. SummaryOcuphire Pharma beats Cellectar Biosciences on 10 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLRB vs. The Competition Export to ExcelMetricCellectar BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.35M$7.03B$5.33B$8.60BDividend YieldN/A7.98%5.14%4.03%P/E Ratio-0.8012.10129.9316.91Price / SalesN/A406.041,691.4398.30Price / CashN/A22.4935.4031.50Price / Book-5.645.784.824.68Net Income-$37.98M$154.13M$118.56M$223.96M7 Day Performance-0.98%-0.41%1.44%0.87%1 Month Performance-7.73%15.39%7.42%4.74%1 Year Performance-18.47%39.58%37.24%29.14% Cellectar Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLRBCellectar Biosciences1.8987 of 5 stars$2.06+1.5%$21.00+919.4%-23.4%$83.57MN/A-0.8110Upcoming EarningsNews CoverageOCUPOcuphire Pharma2.1528 of 5 starsN/A$16.00+∞-57.3%$30.33M$16.45M-2.3914Upcoming EarningsHigh Trading VolumeMLNDMillendo TherapeuticsN/A$0.91-1.1%N/A-74.4%$17.32MN/A0.0012BMEABiomea Fusion3.8007 of 5 stars$9.04-3.5%$30.50+237.4%-11.7%$327.61MN/A-2.2550Analyst RevisionGap UpCMPSCOMPASS Pathways2.263 of 5 stars$4.75-0.2%$47.40+897.9%-29.5%$324.85MN/A-2.06120Earnings ReportHigh Trading VolumeITOSiTeos Therapeutics2.322 of 5 stars$8.81+4.3%$30.50+246.2%-10.8%$321.74M$12.60M-2.9490Positive NewsJSPRJasper Therapeutics2.9625 of 5 stars$21.27+0.4%$74.86+251.9%+215.4%$321.18MN/A-4.1720Gap UpTSHATaysha Gene Therapies1.564 of 5 stars$1.53-9.5%$6.38+316.7%-48.8%$313.56M$15.45M-7.65180Upcoming EarningsNews CoverageGap UpHigh Trading VolumeRZLTRezolute3.9334 of 5 stars$5.50+0.4%$11.57+110.4%+444.0%$307.62MN/A-4.1440Upcoming EarningsAnalyst ForecastNews CoveragePRQRProQR Therapeutics3.0276 of 5 stars$3.73+6.6%$5.88+57.5%+195.9%$304.67M$7.05M-12.86180Gap UpACBAurora Cannabis0.7019 of 5 stars$5.54+2.2%N/A+24.7%$303.83M$278.98M-7.911,073News CoverageGap Down Related Companies and Tools Related Companies OCUP Alternatives MLND Alternatives BMEA Alternatives CMPS Alternatives ITOS Alternatives JSPR Alternatives TSHA Alternatives RZLT Alternatives PRQR Alternatives ACB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLRB) was last updated on 11/6/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredNASDAQ small cap that could be gearing up for a massive short squeeze.A Heavy Short Interest Could Lead to a Monstrous Short Squeeze for this Tiny NASDAQ Healthcare Firm!Huge Alerts | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredStrange new catalyst for gold ($5,000 possible?)Gold: Now legal tender Most Americans missed this big story, but 1 in 5 states have now made gold and silve...Stansberry Research | SponsoredTrump’s Spending Plans Are Here (Here's What You Must Know)Trump's back in the White House, but here's what they're not telling you: his plans could cause inflation to s...Oasis Gold | SponsoredI was wrong. Dead wrong. The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.